論文 - 古橋　眞人

肥満減量術後慢性期の血糖コントロール悪化にセマグルチドが著効した2型糖尿病の症例

赤澤 史子, 小川 俊史, 中田 圭, 佐藤 達也, 伊東 竜哉, 竹政 伊知朗, 古橋 眞人

糖尿病 ( (一社)日本糖尿病学会 )  67 ( 1 ) 37 - 37  2024年01月

肥満減量術後慢性期の血糖コントロール悪化にセマグルチドが著効した2型糖尿病の症例

赤澤 史子, 小川 俊史, 中田 圭, 佐藤 達也, 伊東 竜哉, 竹政 伊知朗, 古橋 眞人

糖尿病 ( (一社)日本糖尿病学会 )  67 ( 1 ) 37 - 37  2024年01月

チルゼパチドが著効した後腹膜滑膜肉腫合併の若年肥満2型糖尿病の症例

大久保 武志, 佐藤 達也, 小川 俊史, 中田 圭, 大和田 渉, 隅田 健太郎, 神津 英至, 矢野 俊之, 古橋 眞人

糖尿病 ( (一社)日本糖尿病学会 )  67 ( 1 ) 38 - 38  2024年01月

中枢性尿崩症合併糖尿病患者に対するSGLT2阻害薬+経口GLP1製剤による治療の1例

中田 圭, 佐藤 達也, 小川 俊史, 大和田 渉, 隅田 健太郎, 神津 英至, 矢野 俊之, 古橋 眞人

糖尿病 ( (一社)日本糖尿病学会 )  67 ( 1 ) 40 - 40  2024年01月

チルゼパチドが著効した後腹膜滑膜肉腫合併の若年肥満2型糖尿病の症例

大久保 武志, 佐藤 達也, 小川 俊史, 中田 圭, 大和田 渉, 隅田 健太郎, 神津 英至, 矢野 俊之, 古橋 眞人

糖尿病 ( (一社)日本糖尿病学会 )  67 ( 1 ) 38 - 38  2024年01月

パッチ式インスリンポンプとリアルタイムCGMを外来で導入し得た症例の検討

吉田 十和, 古橋 眞人, 佐藤 達也

糖尿病 ( (一社)日本糖尿病学会 )  67 ( 1 ) 41 - 41  2024年01月

中枢性尿崩症合併糖尿病患者に対するSGLT2阻害薬+経口GLP1製剤による治療の1例

中田 圭, 佐藤 達也, 小川 俊史, 大和田 渉, 隅田 健太郎, 神津 英至, 矢野 俊之, 古橋 眞人

糖尿病 ( (一社)日本糖尿病学会 )  67 ( 1 ) 40 - 40  2024年01月

Validation of Estimated Small Dense Low-Density Lipoprotein Cholesterol Concentration in a Japanese General Population.

Keisuke Endo, Ryo Kobayashi, Makito Tanaka, Marenao Tanaka, Yukinori Akiyama, Tatsuya Sato, Itaru Hosaka, Kei Nakata, Masayuki Koyama, Hirofumi Ohnishi, Satoshi Takahashi, Masato Furuhashi

Journal of atherosclerosis and thrombosis    2023年12月  [国内誌]

　概要を見る

AIM: A high level of directly measured small dense low-density lipoprotein cholesterol (sdLDL-C) is a strong risk factor for atherosclerotic cardiovascular disease. A method for estimating sdLDL-C by using Sampson's equation that includes levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), non-HDL-C and triglycerides (TG) has recently been proposed. We investigated the validation and exploration of estimated sdLDL-C level. METHODS: The associations between measured and estimated sdLDL-C levels were investigated in 605 Japanese subjects (men/women: 280/325; mean age: 65±15 years) who received annual health check-ups in the Tanno Sobetsu Study, a population-based cohort. RESULTS: Estimated sdLDL-C level was highly correlated with measured sdLDL-C level in all subjects (R2 =0.701), nondiabetic subjects without any medication (n=254, R 2=0.686) and subjects with diabetes mellitus (n=128, R2=0.721). Multivariable regression analysis showed that levels of non-HDL-C, TG and γ-glutamyl transpeptidase (γGTP) were independent predictors of measured sdLDL-C level. In a stratification of the LDL window, all of the subjects with a combination of high non-HDL-C (≥ 170 mg/dL) and high TG (≥ 150 mg/dL) had high levels of measured and estimated sdLDL-C (≥ 35 mg/dL). Furthermore, machine learning-based estimation of sdLDL-C level by artificial intelligence software, Prediction One, was substantially improved by using components of Sampson's equation (R2=0.803) and by using those components with the addition of γGTP and deletion of TC (R2=0.929). CONCLUSIONS: sdLDL-C level estimated by Sampson's equation can be used instead of measured sdLDL-C level in general practice. By building multiple machine learning models of artificial intelligence, a more accurate and practical estimation of sdLDL-C level might be possible.

DOI PubMed

Lipid Metabolism Regulators Are the Possible Determinant for Characteristics of Myopic Human Scleral Stroma Fibroblasts (HSSFs).

Hiroshi Ohguro, Araya Umetsu, Tatsuya Sato, Masato Furuhashi, Megumi Watanabe

International journal of molecular sciences   25 ( 1 )  2023年12月  [国際誌]

　概要を見る

The purpose of the current investigation was to elucidate what kinds of responsible mechanisms induce elongation of the sclera in myopic eyes. To do this, two-dimensional (2D) cultures of human scleral stromal fibroblasts (HSSFs) obtained from eyes with two different axial length (AL) groups, <26 mm (low AL group, n = 2) and >27 mm (high AL group, n = 3), were subjected to (1) measurements of Seahorse mitochondrial and glycolytic indices to evaluate biological aspects and (2) analysis by RNA sequencing. Extracellular flux analysis revealed that metabolic indices related to mitochondrial and glycolytic functions were higher in the low AL group than in the high AL group, suggesting that metabolic activities of HSSF cells are different depending the degree of AL. Based upon RNA sequencing of these low and high AL groups, the bioinformatic analyses using gene ontology (GO) enrichment analysis and ingenuity pathway analysis (IPA) of differentially expressed genes (DEGs) identified that sterol regulatory element-binding transcription factor 2 (SREBF2) is both a possible upstream regulator and a causal network regulator. Furthermore, SREBF1, insulin-induced gene 1 (INSIG1), and insulin-like growth factor 1 (IGF1) were detected as upstream regulators, and protein tyrosine phosphatase receptor type O (PTPRO) was detected as a causal network regulator. Since those possible regulators were all pivotally involved in lipid metabolisms including fatty acid (FA), triglyceride (TG) and cholesterol (Chol) biosynthesis, the findings reported here indicate that FA, TG and Chol biosynthesis regulation may be responsible mechanisms inducing AL elongation via HSSF.

DOI PubMed

Benzalkonium chloride greatly deteriorates the biological activities of human corneal stroma fibroblasts in a concentration-dependent manner.

Araya Umetsu, Yosuke Ida, Tatsuya Sato, Masato Furuhashi, Hiroshi Ohguro, Megumi Watanabe

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie    2023年12月  [国際誌]

　概要を見る

BACKGROUND: Corneal tissues indirectly obtain nutritional needs and oxygen to maintain their homeostasis, and therefore, benzalkonium chloride (BAC) containing ocular instillations for medical therapy may, in turn, induce toxic effects more than expected in corneal tissues, especially the inside stroma layer. METHODS: To evaluate the effects of very low concentrations (10-8%, 10-6%, or 10-4%) of BAC on human corneal stroma, we used two-dimensional (2D) cultures of human corneal stromal fibroblast (HCSF) cells and carried out the following analyses: (1) cell viability measurements, (2) Seahorse cellular bio-metabolism analysis, and (3) the expression of ECM molecules and endoplasmic reticulum (ER) stress-related molecules. RESULTS: In the absence and presence of 10-8%, 10-6%, or 10-4% concentrations of BAC, cell viability deteriorated and this deterioration was dose-dependent. The results showed that maximal mitochondrial respiration was decreased, the mRNA expression of most of ECM proteins was decreased, and ER stress-related molecules were substantially and dose-dependently down-regulated in HCSFs by the BAC treatment. CONCLUSIONS: The findings reported herein indicate that the presence of BAC, even at such low concentrations, is capable of causing the deterioration of cellular metabolic functions and negatively affecting the response to ER stress in HCSF cells resulting in a substantially decreased cellular viability.

DOI PubMed

Coexistence of sarcopenia and self‐reported weight loss is a powerful predictor of mortality in older patients with heart failure

Katsuhiko Ohori, Toshiyuki Yano, Satoshi Katano, Ryohei Nagaoka, Ryo Numazawa, Kotaro Yamano, Yusuke Fujisawa, Hidemichi Kouzu, Nobutaka Nagano, Takefumi Fujito, Ryo Nishikawa, Wataru Ohwada, Masato Furuhashi

Geriatrics &amp; Gerontology International ( Wiley )   2023年12月

　概要を見る

Aim We examined whether the addition of self‐reported weight loss improves the accuracy of prediction of mortality caused by sarcopenia in heart failure (HF) patients. Methods We enrolled 477 HF patients (mean age 77 years) who received combined assessment of sarcopenia and self‐reported weight loss. Sarcopenia was diagnosed according to the criteria of the Asian Working Group for Sarcopenia. If the patients answered “yes” to the question “have you lost 2 kg or more in the past 6 months?”, they were diagnosed as having self‐reported weight loss. Results Sarcopenia and self‐reported weight loss coexisted in 32% of patients. During a median follow‐up period of 763 days, 65 patients (15%) died. Kaplan–Meier curves showed a significantly higher rate of mortality in HF patients with both sarcopenia and self‐reported weight loss than in HF patients with sarcopenia alone. Multivariate Cox proportional hazards analysis showed that the coexistence of sarcopenia and self‐reported weight loss is an independent predictor of mortality in HF patients. Inclusion of the coexistence of sarcopenia and self‐reported weight loss in the baseline model consisting of established prognostic markers significantly improved both the net reclassification index and the integrated discrimination index. Conclusions The coexistence of sarcopenia and self‐reported weight loss is a powerful predictor of mortality in HF patients. Geriatr Gerontol Int 2023; ••: ••–••.

DOI

Systemic sarcoidosis presenting as a rare combination of interstitial nephritis with necrotizing vasculitis and urinary retention due to prostate involvement: a case report.

Arata Osanami, Tomohisa Yamashita, Shintaro Sakurada, Tatsuya Sato, Yuki Kyoda, Tetsuya Shindo, Hiromi Fujita, Yayoi Ogawa, Masato Furuhashi

BMC nephrology   24 ( 1 ) 370 - 370  2023年12月  [国際誌]

　概要を見る

BACKGROUND: Sarcoidosis affects multiple organs and exhibits diverse clinical manifestations. Although tubulointerstitial nephritis is a known feature of renal involvement, necrotizing vasculitis is rare. Furthermore, prostate involvement with urinary retention is unusual in patients with sarcoidosis. Here, we report a case of systemic sarcoidosis with a rare combination of manifestations and different acute kidney injuries. CASE PRESENTATION: A 66-year-old man developed sudden urinary retention and fever. He was diagnosed with prostatitis and admitted to our hospital. An indwelling urethral catheter was inserted, and antimicrobial therapy was initiated; however, the prostatitis was refractory. Computed tomography revealed enlarged mediastinal lymph nodes. Analysis of transbronchoscopic lymph node and prostate biopsies showed epithelioid cell granulomas, suggesting systemic sarcoidosis. During the clinical course, the serum creatinine level rapidly increased to 2.36 mg/dL without oliguria. A kidney biopsy revealed tubulointerstitial injury with moderate lymphohistiocytic infiltration and small-vessel vasculitis in the interstitium. Following oral administration of 60 mg/day prednisolone, the patient's renal function immediately improved, and urinary retention did not recur. CONCLUSIONS: To the best of our knowledge, this is the first reported case of sarcoidosis with two unusual complications. Given its clinical course and pathology, this case is clinically valuable.

DOI PubMed

Relationship between serum iron level and physical function in heart failure patients is lost by presence of diabetes.

Katsuhiko Ohori, Toshiyuki Yano, Satoshi Katano, Ryohei Nagaoka, Ryo Numazawa, Kotaro Yamano, Yusuke Fujisawa, Hidemichi Kouzu, Nobutaka Nagano, Takefumi Fujito, Ryo Nishikawa, Wataru Ohwada, Tatsuya Sato, Masato Furuhashi

ESC heart failure    2023年12月  [国際誌]

　概要を見る

AIMS: Iron deficiency (ID) is common in patients with heart failure (HF) and is reportedly associated with exercise intolerance and impaired quality of life. Iron supplementation therapy in HF patients with ID improves exercise capacity. Conversely, protective roles of iron depletion in the development of diabetes mellitus (DM) and its complications have been proposed. This study aimed to determine the impact of ID on physical function in HF patients with and without DM. METHODS AND RESULTS: We enrolled consecutive patients who were admitted to our institute for HF diagnosis and management. The short physical performance battery (SPPB) was used to evaluate physical function, and low physical function was defined as an SPPB score of <10 points as individuals with SPPB scores of <10 points are most likely to be classified as frail and are at high risk for disability and future adverse events, including death. ID was defined as serum ferritin < 100 or 100-299 ng/mL when transferrin saturation (TSAT) was <20% according to the HF guidelines. Among the 562 HF patients (72 ± 14 years old; 56% male), 329 patients (58%) and 191 patients (34%) had ID and low physical function, respectively. Multivariate logistic regression analysis showed that TSAT as a continuous variable, but not ID, was a predictor of low physical function (odds ratio: 0.980, P = 0.024). Subgroup analysis showed that a significant association between low TSAT and low physical function was lost in HF patients with DM (P for interaction < 0.001). A spline dose-response curve for the relationship between TSAT and risk of low physical function with adjustments for covariates associated with low physical function in non-DM patients was almost linear with an increase in the risk of low physical function as the TSAT increased, but such a relationship was not found in the analyses of DM patients. A lack of close TSAT-SPPB relationship in HF patients with DM was confirmed also in a propensity-score-matched cohort. CONCLUSIONS: TSAT as a continuous variable, but not ID, was independently associated with physical function in HF patients, and a significant association was lost in patients with HF and DM, suggesting a limited impact of iron supplementation therapy in HF patients with DM.

DOI PubMed

Predictive modeling for the development of diabetes mellitus using key factors in various machine learning approaches

Marenao Tanaka, Yukinori Akiyama, Kazuma Mori, Itaru Hosaka, Kenichi Kato, Keisuke Endo, Toshifumi Ogawa, Tatsuya Sato, Toru Suzuki, Toshiyuki Yano, Hirofumi Ohnishi, Nagisa Hanawa, Masato Furuhashi

Diabetes Epidemiology and Management ( Elsevier BV )    100191 - 100191  2023年12月

DOI

Circulating tumor necrosis factor-related biomarkers predict kidney function decline in Japanese patients with diabetes: An observational cohort study.

Maki Murakoshi, Nozomu Kamei, Yusuke Suzuki, Mitsunobu Kubota, Michiyoshi Sanuki, Hirotaka Tashiro, Takumi Iwasawa, Kazunori Kato, Marenao Tanaka, Masato Furuhashi, Tomohito Gohda

Diabetes research and clinical practice   206   111017 - 111017  2023年11月  [国際誌]

　概要を見る

AIMS: Tumor necrosis factor (TNF) receptors (TNFRs: TNFR1 and, TNFR2) are reportedly associated with chronic kidney disease (CKD) progression chiefly in Caucasian patients with diabetes. We assessed the prognostic value of TNF-related biomarkers for CKD progression in Japanese patients with diabetes. METHODS: We estimated TNF-related biomarkers using an enzyme-linked immunosorbent assay in 640 patients with diabetes. Cox proportional hazards analysis was performed to estimate hazard ratios (HRs) per one standard deviation (SD) increase in a log-transformed biomarker. The kidney and the composite outcome were defined as a 30% reduction in estimated glomerular filtration rate (eGFR) from baseline, and kidney outcome plus death before kidney outcome, respectively. RESULTS: During the median follow-up of 5.4 years, 75 (11.7%) patients reached the kidney outcome and 37 (5.8%) died before reaching the kidney outcome. Each SD increase in baseline circulating TNFR1, TNFR2, and ephrin type-A receptor 2 (EphA2) was associated with a higher risk of the kidney outcome independently from baseline eGFR and urine albumin-to-creatinine ratio. However, circulating osteoprotegerin was associated with the composite outcome only. CONCLUSIONS: Elevated TNFR1, TNFR2, and EphA2 were associated with both kidney and composite outcomes in Japanese patients with diabetes.

DOI PubMed

A high level of thyroid-stimulating hormone is a risk factor for the development of chronic kidney disease in men: a 10-year cohort study.

Keisuke Endo, Marenao Tanaka, Tatsuya Sato, Kazuma Mori, Itaru Hosaka, Takuma Mikami, Araya Umetsu, Yukinori Akiyama, Hirofumi Ohnishi, Nagisa Hanawa, Masato Furuhashi

Hypertension research : official journal of the Japanese Society of Hypertension    2023年10月  [国際誌]

　概要を見る

Hypothyroidism has been reported to be associated with chronic kidney disease (CKD). However, the impact of thyroid-stimulating hormone (TSH) on new onset of CKD and its gender dependence remain undetermined. We investigated the association of serum TSH level and the development of CKD defined by estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 or positive for urine protein in 28,990 Japanese subjects who received annual health examinations. After excluding subjects with no data for serum TSH, urinalysis and eGFR and those with CKD at baseline, a total of 10,392 subjects (men/women: 6802/3590, mean age: 48 years) were recruited. During a 10-year follow-up, 1185 men (6.7%) and 578 women (2.9%) newly developed CKD. Multivariable Cox proportional hazard models after adjustment of age, body mass index, smoking habit, hypertension, diabetes mellitus, dyslipidemia, ischemic heart disease and eGFR (≥ 90 mL/min/1.73 m2) showed that the hazard ratio (HR) for the development of CKD in the high TSH (> 4.2 mU/L) group was significantly higher than that in the low TSH (≤ 4.2 mU/L) group in men (HR [95% confidence interval]: 1.41 [1.09-1.83]) but not in women (1.08 [0.77-1.51]). There was a significant interaction between sex and the category of TSH level for the development of CKD (p = 0.02). The adjusted HR with a restricted cubic spline increased with a higher level of TSH in men but not in women. In conclusion, a high level of TSH is associated with an increased risk for the development of CKD in men but not in women.

DOI PubMed

Independent Link Between Use of Mineralocorticoid Receptor Antagonists and Muscle Wasting in Heart Failure Patients Not Receiving Renin-Angiotensin System Inhibitors

Ryo Numazawa, Satoshi Katano, Toshiyuki Yano, Ryohei Nagaoka, Katsuhiko Ohori, Hidemichi Kouzu, Suguru Honma, Yusuke Fujisawa, Kotaro Yamano, Arata Osanami, Masayuki Koyama, Akiyoshi Hashimoto, Masato Furuhashi

Circulation Journal ( Japanese Circulation Society )   2023年10月

DOI

3D culture induction of adipogenic differentiation in 3T3-L1 preadipocytes exhibits adipocyte-specific molecular expression patterns and metabolic functions

Keisuke Endo, Tatsuya Sato, Araya Umetsu, Megumi Watanabe, Fumihito Hikage, Yosuke Ida, Hiroshi Ohguro, Masato Furuhashi

Heliyon ( Elsevier BV )  9 ( 10 ) e20713 - e20713  2023年10月

DOI

Optimal serum 25-hydroxyvitamin D level to prevent sarcopenia in patients with heart failure: insights from a dose-response relationship

Ryohei Nagaoka, Satoshi Katano, Toshiyuki Yano, Ryo Numazawa, Kotaro Yamano, Yusuke Fujisawa, Suguru Honma, Tatsuki Kamoda, Kohei Sato, Hidemichi Kouzu, Katsuhiko Ohori, Masaki Katayose, Akiyoshi Hashimoto, Masato Furuhashi

Nutrition, Metabolism and Cardiovascular Diseases ( Elsevier BV )   2023年10月

DOI

HIF-PH阻害薬の中止因子の検討

宮尾 舞, 石郷 友之, 相神 智宏, 野々山 雅俊, 山下 智久, 小山 雅之, 藤居 賢, 矢野 俊之, 古橋 眞人, 福土 将秀

日本腎臓病薬物療法学会誌 ( 日本腎臓病薬物療法学会 )  12 ( 特別号 ) S200 - S200  2023年10月